<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response-Reference-Cited by-同舟云学术

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

Published:2022-11-29 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ibáñez-Molero Sofía¹,van Vliet Alex¹,Pozniak Joanna²,Hummelink Karlijn³⁴,Terry Alexandra M.¹⁵,Monkhorst Kim⁴,Sanders Joyce⁴,Hofland Ingrid⁴,Landeloos Ewout²,Van Herck Yannick⁶,Bechter Oliver⁶,Kuilman Thomas¹⁷,Zhong Weiwei⁸,Marine Jean-Christophe²,Wessels Lodewyk⁹,Peeper Daniel S.¹

Affiliation:

1. Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands

2. Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium

3. Department of Thoracic oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands

4. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands

5. Current address: Genmab, Utrecht, The Netherlands

6. Department of General Medical Oncology, UZ Leuven Laboratory of Experimental Oncology, Leuven, Belgium

7. Current address: Neogene Therapeutics, Amsterdam, The Netherlands

8. Bristol Myers Squibb, Redwood city, CA, USA

9. Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands

Funder

supported by

Bristol Myers Squibb

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2139074

Reference34 articles.

1. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials

2. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

3. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

4. Tumour-intrinsic resistance to immune checkpoint blockade

5. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition;Cell Death & Disease;2024-02-02

2. CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer;npj Precision Oncology;2024-01-31

3. Near-Infrared Titania Nanoparticle-Based Photoimmunotherapy via Tumor-Microenvironment-Responsive Gene Editing of SerpinB9 for Triple-Negative Breast Cancer;ACS Applied Nano Materials;2024-01-18

4. Phosphoprotein dynamics of interacting T cells and tumor cells by HySic;Cell Reports;2024-01

5. Overexpression of SerpinB9 in non-seminomatous germ cell tumors;Medical Molecular Morphology;2023-11-22